CryoFit

Navigating the complex and rapidly evolving health and wellness industry for a franchise investment presents a significant challenge for discerning entrepreneurs, who seek not just a business, but a pathway to sustained growth and impact without the pitfalls of unproven models or fragmented markets. Understanding the true potential of a Cryofit franchise opportunity requires a deep dive into its foundational history, strategic evolution, and current market positioning. CryoFit, originally established in Austin, Texas, in 2014 by co-founders Sheryl Reeh and Brian Balli, has recently undergone a transformative rebranding to "bioworX: Essentials for Life." This strategic pivot signifies an expansion of its mission beyond its initial pioneering wellness services, now aiming to deliver comprehensive, science-based wellness solutions through an integrative approach encompassing twelve unique modalities. While the corporate address for CryoFit Americas, Inc. remains 1406 Camp Craft Rd., Suite 112, Austin, Texas 78746, and Jeff Reeh is listed as its CEO, the operational focus has shifted significantly under the bioworX banner, where Brian Balli now serves as President & Co-Founder. The original CryoFit brand began offering franchises in 2017 and had grown to 11 locations by February 2023, primarily concentrated in Texas with some presence in Wisconsin; following the rebranding, bioworX has expanded its footprint to 14 locations nationwide, demonstrating a continued growth trajectory despite the ambitious initial goals of the founders in 2015 to reach 50 locations within two years and 250 within five years not being met. However, for the specific legacy "Cryofit" brand, independent database records indicate a current count of 2 total units, both of which are franchised and none are company-owned, reflecting a distinct operational snapshot within its broader evolution. This brand matters to franchise investors by offering a foothold in the booming $4.5 trillion global wellness industry, positioning itself as a guide for entrepreneurs looking to optimize performance and support natural healing processes through cutting-edge modalities. PeerSense provides this independent analysis, meticulously dissecting the brand's profile to offer an authoritative perspective, distinctly separate from any marketing claims.

The industry landscape in which bioworX (formerly CryoFit) operates is characterized by robust growth and evolving consumer preferences, offering significant tailwinds for well-positioned franchise concepts. The global cryotherapy market, a core segment of bioworX's offerings, was valued at $6.39 billion in 2021 and is projected to advance at a compound annual growth rate (CAGR) of 7.2% by 2030, indicating a consistent expansion of demand for these specialized services. Alternative market analyses further underscore this growth, with projections placing the market size at $207.5 million in 2024, anticipated to reach $325.3 million by 2030, growing at a CAGR of 7.8% from 2025 to 2030. Mordor Intelligence provides another perspective, estimating the market size to increase from $322.04 million in 2025 to $464.61 million by 2031, with a CAGR of 6.45% over 2026-2031. North America leads this market, commanding a substantial revenue share of 57.4% in 2024, with the U.S. market alone accounting for an impressive 89.4% of the North American segment, highlighting a concentrated and lucrative domestic opportunity. Cryochambers dominate the product segment, holding a 51.7% share in 2024, while beauty and wellness applications drive demand with a 32.5% revenue share, and cryotherapy centers themselves capture the largest end-use market share at 48.8% in 2024. Beyond cryotherapy, the broader global outpatient care market, which encompasses many of bioworX's integrative services, was valued at approximately $48.5 billion in 2024 and is predicted to surge to around $157.5 billion by 2034, exhibiting a significant CAGR of roughly 12.5% between 2025 and 2034. This growth is fueled by key consumer trends, including an increasing preference for convenience, cost-effectiveness, and quicker access to healthcare services, alongside a rising recognition of cryotherapy's benefits for pain management, muscle recovery, and overall wellness. The market is also witnessing a shift towards non-invasive treatments to reduce risks associated with traditional surgeries, further broadened by increased sports participation and social media promotion. These secular tailwinds create a fertile ground for a franchise like bioworX, which offers a diversified portfolio of science-based wellness solutions, positioning it to capitalize on a market that, while fragmented, is increasingly consolidating around comprehensive, integrative approaches.

For a potential investor considering the Cryofit franchise cost and overall Cryofit franchise investment, a detailed understanding of the financial requirements is paramount. The initial franchise fee for a CryoFit (now bioworX) unit is reported with slight variations, with one source indicating a minimum and maximum upfront franchise fee of $35,000, while another specifies a franchise fee of $39,000 for CryoFit. This fee represents the upfront cost for the rights to operate under the brand's system and access its proprietary knowledge. The total investment necessary to begin operation of a CryoFit facility has also seen varying figures, with one range cited from $141,550 to $289,000, and another providing a broader estimate of $275,000 to $350,000. Following the rebranding and expansion of modalities, the total investment for a bioworX franchise ranges from $299,050 to $446,700, reflecting the enhanced scope of services and facility requirements. These comprehensive costs typically include the initial franchise fee, essential equipment, initial marketing expenditures to launch the business, and crucial working capital to sustain operations during the initial ramp-up phase. Beyond the initial outlay, franchisees are subject to ongoing fees, including a royalty rate structured as 6% of gross sales, paid semi-monthly, which aligns with general industry information suggesting royalties typically range from 4-8% of gross sales. Additionally, franchisees contribute to a system-wide advertising fund, remitting 1% of gross sales semi-monthly, to support collective brand promotion and marketing initiatives. Prospective franchisees are also required to meet specific liquid capital and net-worth thresholds to ensure financial stability. The minimum cash required is reported as $250,000 or $257,000, indicating a substantial liquid asset requirement. Furthermore, a net-worth requirement of $350,000 is specified for potential owners, demonstrating the brand's preference for financially robust candidates. In terms of financing, bioworX is recognized as an SBA-approved franchise, which facilitates access to Small Business Administration lending programs, allowing prospective owners to collaborate with participating financial institutions. Given these financial parameters, the Cryofit franchise investment positions itself as a mid-tier to premium opportunity within the wellness sector, requiring significant capital but offering the backing of an established and evolving brand.

The operational model and comprehensive support system offered by bioworX, formerly CryoFit, are designed to empower franchisees from the outset, mitigating the inherent risks associated with launching a new business. The franchisor emphasizes a commitment to providing extensive training and robust corporate support, ensuring that new owners are well-equipped to manage their wellness centers effectively. Daily operations for a franchisee involve managing a diverse range of science-based wellness modalities, including whole-body cryotherapy, IV drip infusions, infrared saunas, injectable vitamins, and compression boots, alongside the twelve unique modalities introduced under the bioworX brand. The brand boasts a low overhead operating model, coupled with in-depth training and a proven business framework. The training program is an intensive, hands-on experience conducted at a corporate facility in San Antonio, covering a wide array of critical operational aspects. These sessions comprehensively address business management strategies, effective marketing and social media deployment, the intricacies of facility and equipment operations and maintenance, essential cost management techniques, and the specialized control and purchasing of nitrogen gas. This holistic approach ensures franchisees gain a deep understanding of both the business and technical facets of their wellness center. In terms of ongoing support, CryoFit assists new owners with crucial location criteria, leveraging its network to help them find commercial real estate brokers in their target areas to aid with lease negotiations. Support extends through the construction and design phases of the facility, providing guidance to ensure brand consistency and operational efficiency. While the brand prefers franchisees to be actively involved in their store's operations, reflecting an owner-operator model, it is not a mandatory requirement, offering flexibility for multi-unit developers or those with strong management teams. Multi-unit development opportunities are explicitly available, indicating the brand's scalability and suitability for ambitious entrepreneurs looking to expand their portfolio. The bioworX brand specifically underscores its robust business model, comprehensive training programs, and premier marketing support, all meticulously designed to ensure long-term franchisee success within the competitive wellness market.

Regarding financial performance, potential investors in a Cryofit franchise should note that Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document for Cryofit. This means specific profit figures for CryoFit franchise owners are not publicly available through the FDD. Under the Federal Franchise Rule, franchisors are not legally mandated to provide earnings information in Item 19 of their Franchise Disclosure Document. However, if any financial performance claims are made, they must be meticulously disclosed and substantiated within this section. It is important to understand that Item 19 may include various financial metrics such as revenue, sales, expenses, or profit information, but revenue data alone does not definitively indicate profitability. The absence of publicly available profit data necessitates that potential franchisees conduct exceptionally thorough due diligence and engage directly with the franchisor for any Item 19 disclosures that may be available, and critically, to speak with existing franchisees. Despite the lack of specific profit disclosures, several market and operational indicators can offer insights into the potential for Cryofit franchise revenue generation. The global wellness industry, valued at $4.5 trillion, provides a vast addressable market, with the cryotherapy market alone projected for significant growth, advancing at a CAGR of 7.2% by 2030 from its $6.39 billion valuation in 2021. Other forecasts show the cryotherapy market reaching $325.3 million by 2030 with a 7.8% CAGR from 2025-2030, or $464.61 million by 2031 with a 6.45% CAGR over 2026-2031, suggesting a healthy and expanding revenue environment. The broader global outpatient care market, valued at $48.5 billion in 2024, is predicted to grow to $157.5 billion by 2034, exhibiting a substantial CAGR of 12.5% between 2025 and 2034, further highlighting the robust demand for services offered by bioworX. Historically, CryoFit began franchising in 2017, and by February 2023, it had grown to 11 locations, which then expanded to 14 locations nationwide under the bioworX brand. While the founders' initial ambitious goals of 50 locations within two years and 250 within five years in 2015 were not realized, the consistent growth in unit count from its founding to its current state under bioworX suggests a steady, albeit measured, expansion. Franchisee testimonials, such as Chelsea J., who bought her first CryoFit in August 2019 and opened a second in February 2021, reported achieving her financial goals with continuous corporate support, offering qualitative evidence of potential success. Similarly, Chad B. noted how owning a CryoFit franchise aligned with his passion for health and wellness, indicating a business model that can resonate with owner-operators. The independent FPI Score for Cryofit is 49, categorized as "Fair," providing an objective, albeit general, performance indicator from an external database. This score, combined with strong market growth projections and positive franchisee feedback, suggests that while specific financial disclosures are absent, the underlying market conditions and operational support could support a viable business.

The growth trajectory of CryoFit, now bioworX, reflects a strategic evolution aimed at capitalizing on the expanding wellness market, albeit with a measured pace compared to initial aggressive projections. CryoFit initiated its franchising efforts in 2017. From its founding in 2014, the brand expanded to 11 locations by February 2023. While the founders had set ambitious targets in 2015 to reach 50 locations within two years and 250 within five years, these specific unit count goals were not met. However, the rebranding to bioworX has coincided with further expansion, with the new entity now operating 14 locations nationwide, demonstrating a net increase in units and a renewed focus on growth. The specific "Cryofit" brand name, as per independent database records, indicates 2 franchised units, reflecting a particular snapshot of its legacy operations. The most significant recent corporate development is the comprehensive rebranding to "bioworX: Essentials for Life," which represents a fundamental shift from a singular wellness service provider to a holistic brand offering an expanded suite of services. This transformation involves the incorporation of twelve unique modalities, significantly broadening its offerings beyond the core services of whole-body cryotherapy, IV drip infusions, infrared saunas, injectable vitamins, and compression boots. This expansion is strategically designed to lower inflammation and improve circulation, positioning bioworX as a leader in supporting the body's natural healing processes and optimizing performance. Leadership changes accompany this rebranding, with co-founder Brian Balli now serving as the President & Co-Founder of bioworX, indicating a continuity of founding vision within the new strategic direction. The competitive moat for bioworX is built upon this integrative approach, offering a diverse portfolio of science-based wellness solutions that cater to a wide range of client needs, from fitness enthusiasts and athletes seeking recovery to individuals focused on general health and well-being. The company's focus on an integrative approach with multiple modalities provides a distinct advantage over single-service providers. Furthermore, its SBA-approved franchise status enhances its appeal to prospective owners by facilitating access to financing. The brand is actively adapting to current market conditions by capitalizing on the booming $4.5 trillion global wellness industry and responding to consumer trends that favor non-invasive treatments and comprehensive health solutions. This strategic evolution, marked by rebranding and service expansion, is designed to create a resilient and competitive franchise model.

The ideal franchisee for a bioworX (formerly CryoFit) center is someone deeply aligned with the brand's mission to provide comprehensive, science-based wellness solutions, although specific prior experience is not explicitly mandated. While the brand prefers franchisees to be actively involved in their store's operations, indicating a leaning towards an owner-operator model, it is not a mandatory requirement, which allows for flexibility for those with strong management teams or multi-unit aspirations. Testimonials from existing franchisees, such as Chad B., highlight a lifelong passion for health and wellness and a desire to help clients find suitable wellness protocols, suggesting that a genuine interest in the industry and its benefits is a key attribute. The availability of multi-unit development opportunities signals that the brand is seeking ambitious entrepreneurs capable of scaling operations across multiple locations. Geographically, CryoFit's initial footprint included locations primarily in Texas and some in Wisconsin, demonstrating success in diverse markets; the rebranded bioworX has expanded to 14 locations nationwide, indicating a broader territorial focus and potential for growth across the country. The company supports new owners by assisting with location criteria and connecting them with commercial real estate brokers in their area, suggesting a strategic approach to market penetration rather than a passive territory assignment. While the specific timeline from signing to opening, franchise agreement term length, or details on transfer and resale considerations are not explicitly provided, the robust support structure for site selection, construction, and design implies a guided and structured launch process for new franchisees. The significant liquid capital requirement of $250,000 or $257,000 and a net-worth requirement of $350,000 further define the ideal candidate as a financially secure individual or group capable of making a substantial Cryofit franchise investment.

For franchise investors contemplating an entry into the high-growth wellness sector, bioworX, formerly CryoFit, presents a compelling franchise opportunity that warrants serious due diligence. The brand's strategic rebranding to "bioworX: Essentials for Life" and its expansion to twelve unique, science-backed modalities position it as a forward-thinking player in the $4.5 trillion global wellness industry. This evolution from a pioneer in wellness services to a holistic provider of solutions for lowering inflammation and improving circulation aligns perfectly with surging consumer demand for non-invasive treatments and comprehensive health optimization. The robust market projections for both cryotherapy (projected to reach $325.3 million by 2030 at a 7.8% CAGR) and the broader outpatient care market (expected to hit $157.5 billion by 2034 with a 12.5% CAGR) underscore a fertile environment for growth. While specific Item 19 financial performance data is not disclosed, the brand's growth from 11 locations to 14 nationwide under the new identity, coupled with positive franchisee testimonials and an independent FPI Score of 49 (Fair), suggests a viable operational model supported by comprehensive training and premier marketing support. This opportunity is for entrepreneurs ready to commit significant capital, with a Cryofit franchise cost ranging from $299,050 to $446,700 for bioworX, and meeting liquid capital requirements of $250,000 or $257,000 and a net worth of $350,000. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools. Explore the complete Cryofit franchise profile on PeerSense to access the full suite of independent franchise intelligence data.